Aytu BioPharma (NASDAQ:AYTU – Get Free Report) released its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.24, Zacks reports. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The firm had revenue of $16.11 million during the quarter, compared to the consensus estimate of $12.28 million.
Aytu BioPharma Price Performance
Shares of AYTU stock traded up $0.10 during trading on Tuesday, hitting $2.23. The company had a trading volume of 256,744 shares, compared to its average volume of 49,260. Aytu BioPharma has a one year low of $1.65 and a one year high of $3.07. The firm has a market capitalization of $23.93 million, a P/E ratio of -0.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The stock’s 50-day moving average price is $2.21 and its 200 day moving average price is $2.33.
Analyst Ratings Changes
A number of brokerages have recently commented on AYTU. Ascendiant Capital Markets lifted their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $10.75.
About Aytu BioPharma
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.
Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.
Further Reading
- Five stocks we like better than Aytu BioPharma
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
